Modality
Vaccine
MOA
HER2
Target
FXIa
Pathway
Cell Cycle
Ovarian Ca
Development Pipeline
Preclinical
Jun 2022
→ Aug 2027
PreclinicalCurrent
NCT04821092
1,411 pts·Ovarian Ca
2022-06→2027-08·Recruiting
1,411 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-08-091.4y awayInterim· Ovarian Ca
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
Preclinical
Recruit…
Catalysts
Interim
2027-08-09 · 1.4y away
Ovarian Ca
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04821092 | Preclinical | Ovarian Ca | Recruiting | 1411 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| TAK-9344 | Takeda | Phase 3 | CGRP |